iData Insights

Bipolar Disorder (Manic Depression) - Pipeline Review, H2 2015 Is Released

Press Release   •   Feb 03, 2016 14:47 IST

This report provides comprehensive information on the therapeutic development for Bipolar Disorder (Manic Depression), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bipolar Disorder (Manic Depression) and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Bipolar Disorder (Manic Depression) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Bipolar Disorder (Manic Depression) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Bipolar Disorder (Manic Depression) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Bipolar Disorder (Manic Depression) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Bipolar Disorder (Manic Depression) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Bipolar Disorder (Manic Depression) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Browse Complete Report with TOC

To Get Sample Copy of Report visit

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Bipolar Disorder (Manic Depression) Overview 10

Therapeutics Development 11

Pipeline Products for Bipolar Disorder (Manic Depression) - Overview 11

Pipeline Products for Bipolar Disorder (Manic Depression) - Comparative Analysis 12

Bipolar Disorder (Manic Depression) - Therapeutics under Development by Companies 13

Bipolar Disorder (Manic Depression) - Therapeutics under Investigation by Universities/Institutes 15

Bipolar Disorder (Manic Depression) - Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Bipolar Disorder (Manic Depression) - Products under Development by Companies 19

Bipolar Disorder (Manic Depression) - Products under Investigation by Universities/Institutes 21

Bipolar Disorder (Manic Depression) - Companies Involved in Therapeutics Development 22

Aequus Pharmaceuticals Inc. 22

ANP Technologies, Inc. 23

AstraZeneca Plc 24

Convergence Pharmaceuticals Ltd. 25

D-Pharm Ltd. 26

Delpor, Inc. 27

Intas Pharmaceuticals Ltd. 28

Intra-Cellular Therapies, Inc. 29

Johnson & Johnson 30

KemPharm, Inc. 31

Neurocrine Biosciences, Inc. 32

Omeros Corporation 33

Otsuka Holdings Co., Ltd. 34

Pfizer Inc. 35

Reviva Pharmaceuticals Inc. 36

SK Biopharmaceuticals Co., Ltd. 37

Sumitomo Dainippon Pharma Co., Ltd. 38

Teva Pharmaceutical Industries Limited 39

Zogenix, Inc. 40

Zysis Limited 41

Bipolar Disorder (Manic Depression) - Therapeutics Assessment 42

Assessment by Monotherapy Products 42

Assessment by Target 43

Assessment by Mechanism of Action 45

Assessment by Route of Administration 47

Assessment by Molecule Type 49

Drug Profiles 51

ANP-010 - Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

aripiprazole - Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

aripiprazole CR - Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

aripiprazole ER - Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

CNV-1061436 - Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

DP-VPA - Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

Drug for Bipolar Disorder - Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

Drug for Cancer and Neurodegenerative Disease - Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

ebselen - Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

Endoxifen - Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

ITI-007 - Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

JNJ-18038683 - Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

KP-303 - Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

lurasidone hydrochloride - Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

NP-202 - Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

paliperidone palmitate - Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

PGW-5 - Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

quetiapine fumarate ER - Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

risperidone - Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

risperidone - Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

RP-5063 - Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

SKL-PSY - Drug Profile 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

Small Molecule for Bipolar Disorder - Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

Small Molecule to Antagonize GPR78 for Bipolar Disorder and Schizophrenia - Drug Profile 80

Product Description 80

Mechanism of Action 80

R&D Progress 80

Small Molecule to Inhibit VMAT-2 for Schizophrenia, Bipolar Disorder and Movement Disorders - Drug Profile 81

Product Description 81

Mechanism of Action 81

R&D Progress 81

Small Molecule to Target GPR50 for CNS and Metabolic Disorders - Drug Profile 82

Product Description 82

Mechanism of Action 82

R&D Progress 82

Small Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System - Drug Profile 83

Product Description 83

Mechanism of Action 83

R&D Progress 83

Synthetic Peptides to Inhibit IMPase for Bipolar Disorder - Drug Profile 84

Product Description 84

Mechanism of Action 84

R&D Progress 84

YKP-3089 - Drug Profile 85

Product Description 85

Mechanism of Action 85

R&D Progress 85

ziprasidone mesylate - Drug Profile 87

Product Description 87

Mechanism of Action 87

R&D Progress 87

Read More

About Us:

iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.

iData Insights

Tel: 1-866-237-2965


AboutiData Insights

We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future project.